Expanding the biomarker landscape to include LIF/LIFR, CLDN18.2, FGFR2b, and other emerging targets is critical to advancing personalized treatment strategies and improving survival outcomes for patients with advanced gastric cancer. The gene discussed is LIFR; the disease is gastric cancer.